|
|
|
|
|
 |
Orthopedic Patients
|
|
| |
|
Orthopedic Products Under Development
The orthopedic and sports injury markets have recently experienced increased demand towards adoption of biologically active treatments, which seek to stimulate the body's own capabilities for regeneration of tissue at the injury sites. The Company is developing a family of product candidates for the treatment of a variety of orthopedic applications. BioMimetic Therapeutics' Augment™ product candidate combines rhPDGF-BB with proprietary resorbable delivery scaffolds.
Augment™ Bone Graft
BioMimetic is developing Augment™ Bone Graft for use in open surgical treatment of fractures and bone fusions where the use of bone graft, a material used to augment bone healing, is indicated. Augment Bone Graft is designed to be placed directly into an open surgical site to stimulate bone regeneration. The combination of the two Augment Bone Graft components, recombinant human platelet-derived growth factor (rhPDGF-BB) and Beta-tricalcium phosphate (β-TCP), is key to the product's overall effectiveness. rhPDGF is intended to provide the biological stimulus for tissue regeneration by stimulating the in-growth and proliferation of osteoblasts, cells responsible for the formation of bone, while β-TCP provides a framework or scaffold for new bone growth to occur.
Augment™ Injectable Bone Graft
BioMimetic is developing an injectable product, Augment™ Injectable Bone Graft, for the treatment of fractures not requiring surgery and for prophylactic bone augmentation. The Augment Injectable Bone Graft product combines rhPDGF-BB with an injectable bone matrix.
To learn more about the Augment™ product candidates, please click on a topic below: |
| |
 |
| |
|
|
| |
 |
|
|
| |
| |
|
|
|
|
|
